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Acute cardiac tamponade requires urgent diagnosis and treatment. Spontaneous hemopericardium leading to cardiac tamponade
as an initial manifestation of essential thrombocythemia (ET) has never been reported in the literature. We report a case
of a 72-year-old Caucasian female who presented with spontaneous hemopericardium and tamponade requiring emergent
pericardiocentesis. The patient was subsequently diagnosed to have ET. ET is characterized by elevated platelet counts that can
lead to thrombosis but paradoxically it can also lead to a bleeding diathesis. Physicians should be aware of this complication so
that timely life-saving measures can be taken if this complication arises.
1.Introduction
Pericardial diseases principally manifest as pericarditis or
pericardial eﬀusion. Pericardial eﬀusions resulting in cardiac
tamponade can occur from a number of causes, including
pericarditis, malignancy, acute myocardial infarction, end-
stage renal disease, congestive heart failure, collagen vascular
disease, and viral and bacterialinfections. Hemopericardium
and resulting tamponade can result from any form of chest
trauma, free wall rupture following myocardial infarction,
retrograde bleeding into the pericardial sac following aortic
root(typeAaortic)dissection, as a complicationofany inva-
sivecardiacprocedure,anticoagulation, andacuteleukemias.
In this paper, we describe a case of cardiac tamponade
resulting from hemopericardium as an initial manifestation
of essential thrombocythemia (ET).
2.CasePresentation
A 72-year-old Caucasian female presented to her primary
care physician for ear pain. She was prescribed nonsteroidal
anti-inﬂammatory drugs (NSAIDs) for her pain. A week
later, she presented to the emergency department (ED) with
episodes of chest pressure, worsening shortness of breath,
and orthopnea. The patient had no known chronic medical
illnesses in the past and was not on any other prescription
medications. She had a 50-pack year history of smoking.
On physical examination, her heart rate was 115beats/
minuteandbloodpressurewas123/44mmofHg.Othervital
signs were within normal limits. She had jugular venous dis-
tension on neck examination. Cardiovascular examination
revealed tachycardia and positive pulsus paradoxus. Chest
examination was unremarkable.
Laboratory data showed normal electrolytes and renal
functions. Her white count was elevated at 12,900cells/mic-
roliter, hemoglobin was marginally low at 11.2g/dl, and
platelet count was elevated at 745,000cells/microliter. Cell
diﬀerential was within normal limits. Cardiac biomarkers
were within normal limits. TSH level was 3.57mIU/L.
Electrocardiogram (ECG) showed normal sinus rhythm and
left atrial enlargement. There were no electrical alternans or
changes of pericarditis on the ECG.2 Cardiology Research and Practice
Chest X-ray showed cardiomegaly and small left sided
pleural eﬀusion. Computed tomography (CT) scan of the
chest in the EDshowed a moderate-sized pericardial eﬀusion
and a small leftpleuraleﬀusion.Cardiologyconsultationwas
obtained due to the presence of pericardial eﬀusion.
A transthoracic echocardiogram conﬁrmed pericardial
eﬀusion with evidence of tamponade physiology (Figure 1).
The patient was taken to cardiac catheterization laboratory
and pericardiocentesis was done. A total of 300mL of
hemorrhagic ﬂuid was drained during the initial procedure.
Drainage of pericardial ﬂuid resulted in immediate improve-
ment of patient’s symptoms. A pigtail catheter was left in
place and the patient was transferred to coronary care unit.
Over next two days, additional 310mL of hemorrhagic ﬂuid
was drained and subsequently pigtail catheter was removed.
Pericardial ﬂuid examination was unremarkable for
any evidence of malignancy or infection. The etiology of
hemorrhagic pericardial eﬀusion was unclear even after
extensive evaluation for malignancy, infection, autoimmune
disease, or any other obvious systemic disease.
The patient continued to have elevated platelet count
throughout the hospital stay with the highest platelet count
being855,000cells/microliter.Shedeniedanyhistoryofprior
thrombotic or bleeding episodes. The elevation in platelet
count was thought to be due to reactive thrombocytosis.
The patient was discharged on fourth hospital day. She was
instructed to followup with her primary care physician in
two weeks with complete blood count to ensure resolution
of thromobycytosis.
At followup, the patient continued to have elevated
platelet counts. She was referred for hematology evaluation.
A peripheral blood smear, bone marrow aspiration, and
core biopsy were done for further evaluation of throm-
bocytosis. Peripheral blood smear showed occasional giant
plateletswithnoplateletaggregates.Therewerenoimmature
myeloid forms. Bone marrow aspirate showed prominent
megaloblastoid change and increased number of megakary-
ocytes. Core biopsy also showed increased number of
megakaryocytes. The megakaryocytes exhibited large hyper-
segmented nuclei with occasional megakaryocytic mitoses.
Flow Cytometry was negative for any immunophenotypic
abnormalities. Fluorescence in situ hybridization (FISH)
for BCR-ABL translocation was negative arguing strongly
against chronic myeloid leukemia. JAK 2 real-time PCR
assay was negative for JAK2 V617 mutation. Thus, bone
marrow biopsy showed megakaryocytic hyperplasia with
dysmegakaryopoiesis consistent with ET.
3.Discussion
Pericardial eﬀusions can be serous or hemorrhagic. The
etiology of pericardial eﬀusion is often inﬂuenced by the
geographical region and patient-related factors. Hemor-
rhagic pericardial eﬀusions often have diﬀerent etiologies
than serous eﬀusions. In a retrospective study done by Atar
et al., the most common cause of hemorrhagic eﬀusions
was found to be iatrogenic (31%) namely, secondary to
invasive cardiac procedures followed by malignancies [1].
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Figure 1: Subcostal view of hemorrhagic pericardial eﬀusion.
(Thereisacollapseoftherightventricularfreewallduringdiastole.)
Bleeding diathesis leading to spontaneous hemopericardium
secondary to congenital coagulation defect has been sparsely
reported in the literature [2–4].
ET is currently classiﬁed among the bcr/abl negative,
“Classic” myeloproliferative disorders (MPDs), which also
include polycythemia vera (PV) and primary myeloﬁbrosis
(PMF) [5, 6]. Each of these MPDs represents a stem cell
derived clonal myeloproliferation. ET is characterized by
megakaryocyte expansion leading to increased platelets. ET
is an uncommon disease with prevalence of 2-3 cases per
million. Median age at diagnosis is usually between 65–
75years with female preponderance. The life expectancy of
ET patients is generally long and similar to that of an age-
matched normal population [7]. Many patients with ET
are asymptomatic, but a large number of them manifest
symptoms or signs of bleeding, usually as ecchymoses or
mucosal hemorrhage, or microvascular thrombosis, usually
as erythromelalgia, digital ischemia, or transient ischemic
attack[8,9].Theriskofthrombohemorrhagic complications
remains unpredictable in individuals. The initial presen-
tation in our patient was spontaneous hemopericardium
that required emergency pericardiocentesis. Bleeding in ET
is thought to be secondary to Acquired Von Willebrand
disease (AVWD) and due to qualitative platelet defects.
The main sites aﬀected are skin, mucous membranes,
and gastrointestinal tract. Severe bleeding is rare but fatal
intracranial bleeding has been reported. AVWD in ET
patients is characterized by the loss of large von Willebrand
factor (VWF) multimers that results in a functional defect
of the VWF, with increasing platelet counts (usually >1.5
million). Normalization of the platelet count results in
normal plasma VWF multimeric distribution and regression
of the hemorrhagic tendency [10]. Serious hemorrhages
m a yb et r i g g e r e db ys i m u l t a n e o u sa n t i t h r o m b o t i ct h e r a p y
with anticoagulants, antiplatelet therapy, and NSAIDs. We
believe that hemorrhagic conversion of pericardial eﬀusion
in our patient was triggered by NSAID therapy. However,
we cannot exclude the possibility of viral syndrome resulting
in pericarditis with subsequent conversion to hemorrhagicCardiology Research and Practice 3
pericardial eﬀusion from bleeding complications related to
ET. Kayrak et al. reported a similar case of a patient with
essential thrombocythemia treated with acetylsalicylic acid,
which resulted in hemorrhagic pericardial eﬀusion [11]. The
patient was successfully treated with clopidogrel therapy
withoutany hemorrhagic or thromboticevent.Averbackand
Moinuddin describe a case of pericardial eﬀusion secondary
to essential thrombocythemia [12]. However, the patient
had trilineage hyperplasia and authors describe autopsy
features consistent with agnogenic myeloid metaplasia with
predominant megakaryocytic proliferation. The diagnosis of
ET on the basis of current WHO criteria is questionable
in this case. Thus, we believe that our case is the ﬁrst one
of ET manifesting with spontaneous hemopericardium as
the initial manifestation. Also, the diagnosis of ET in our
patient was made based on WHO criteria [13]. In ET, bone
marrow ﬁndings are remarkable forthepresenceoflarge, but
mature-appearing, megakaryocytes with deeply lobulated
and hyperlobulated nuclei that are most often dispersed
throughout the biopsy sections [14]. Our patient did have
morphological megakaryocyte abnormality consistent with
diagnosis of ET.
Pericardial eﬀusion related to ET should be treated
based on current standards of care. Patients with cardiac
tamponade require urgent pericardiocentesis. Bleeding com-
plications may be prevented by avoiding use of high-dose
aspirin and NSAIDs.In patientswithbleeding complications
related to ET and AVWD, treatment of thrombocytosis may
be considered [15]. Patients with ET requiring antiplatelet
therapy can be treated with clopidogrel therapy [11].
To summarize, spontaneous hemopericardium is infre-
quentlyencountered among patients with ET, and its clinical
recognition may be diﬃcult. Therefore, in patients with ET
who manifest acute dyspnea or clinical signs of hemody-
namic embarrassment, hemopericardium and tamponade
should be ruled out. Pericardiocentesis is life saving in these
patients since their clinical course is otherwise relatively
benign.
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